Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Inhibikase Therapeutics, Inc. (IKT) had Income from Continuous Operations of $-48.26M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-48.26M |
|
-- |
|
-- |
|
$51.97M |
|
$-51.97M |
|
$3.72M |
|
$-48.26M |
|
$-48.26M |
|
$-48.26M |
|
|
Income from Continuous Operations |
$-48.26M |
$-48.26M |
|
$-48.26M |
|
$-51.97M |
|
$-51.91M |
|
98.31M |
|
98.31M |
|
$-0.49 |
|
$-0.49 |
|
| Balance Sheet Financials | |
$180.11M |
|
-- |
|
$1.10M |
|
$181.20M |
|
$8.30M |
|
-- |
|
-- |
|
$8.30M |
|
$172.90M |
|
$172.90M |
|
$172.90M |
|
131.69M |
|
| Cash Flow Statement Financials | |
$-27.79M |
|
$2.05M |
|
$108.46M |
|
$56.49M |
|
$139.22M |
|
$82.73M |
|
$15.31M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
21.70 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-27.80M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-27.91% |
|
-27.91% |
|
-26.63% |
|
-27.91% |
|
$1.31 |
|
$-0.28 |
|
$-0.28 |
|